Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2008

View Archived Issues

FDA assigns priority review status to sanofi-aventis' NDA for Multaq in atrial fibrillation

Study examines role of insulin signaling in early Alzheimer's disease

Studies in vitro, in vivo display activity of gamma-secretase inhibitor GSI-953

Novel vitamin/nutriceutical formulation improves cognitive decline and behavioral symptoms

Mechanism of action discovered for the novel TNF-alpha production inhibitor SA-13353

Recent highlights at Elan

Cortex reports positive results from RD-02 phase IIa clinical trial of Ampakine in RD

Sound's chemoprotectant drug cleared for phase II hearing loss trial

Hematide phase III program cleared to continue by DMC

Metabasis and Roche collaborate in HCV

New data on TMC-278, a next-generation NNRTI, presented at the International AIDS Conference

Xanodyne reports positive results from two phase III clinical trials of tranexamic acid

Geron initiates enrollment in phase I/II clinical trial of GRN-163L in breast cancer

GTC Biotherapeutics submits final portion of BLA for ATryn to FDA

Innocoll completes dosing in phase II clinical trial of CollaRx in postoperative pain

Archemix and Ribomic sign license agreement for aptamers against multiple targets

FDA extends review timeline by 3 months for Centocor's BLA for ustekinumab

Lixte's compounds for brain tumors demonstrate activity in pancreatic cancer models

Good antiviral activity of Achillion's elvucitabine in phase II study

Novel JAK3 inhibitors described in patent literature

Novel agents for diagnosis of AD discussed in Nihon Medi-Physics patent

New agents for gastrointestinal disorders revealed in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...